Key statistics
On Friday, Novo Nordisk A/S (NOV:HAM) closed at 104.58, 25.40% above the 52 week low of 83.40 set on Oct 04, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 104.90 |
---|---|
High | 105.00 |
Low | 102.00 |
Bid | 104.52 |
Offer | 104.84 |
Previous close | 104.86 |
Average volume | 1.54k |
---|---|
Shares outstanding | 3.39bn |
Free float | 2.11bn |
P/E (TTM) | 38.74 |
Market cap | 2.64tn DKK |
EPS (TTM) | 20.09 DKK |
Annual div (ADY) | 1.33 EUR |
---|---|
Annual div yield (ADY) | 1.27% |
Div ex-date | Aug 15 2024 |
Div pay-date | Aug 19 2024 |
Data delayed at least 15 minutes, as of Oct 04 2024 17:02 BST.
More ▼
Announcements
- Novo Nordisk A/S – Share repurchase programme
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed
- Novo Nordisk A/S: Wegovy® recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improved physical function
- Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
- Novo Nordisk's sales increased by 24% in Danish kroner and by 25% at constant exchange rates to DKK 133.4 billion in the first six months of 2024
- European regulatory authority adopts a positive opinion for an update of the Wegovy® label to reflect risk reduction of major adverse cardiovascular events
- Novo Nordisk receives Complete Response Letter in the US for once-weekly basal insulin icodec
- Novo Nordisk stops the ocedurenone CLARION-CKD trial and recognises impairment loss
- Novo Nordisk announces 4.1 billion USD investment to expand US manufacturing capacity adline
More ▼